These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 16306166)
1. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. Little MA; Bhangal G; Smyth CL; Nakada MT; Cook HT; Nourshargh S; Pusey CD J Am Soc Nephrol; 2006 Jan; 17(1):160-9. PubMed ID: 16306166 [TBL] [Abstract][Full Text] [Related]
2. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. Feldmann M; Pusey CD J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928 [TBL] [Abstract][Full Text] [Related]
3. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Kiely PD; Gillespie KM; Oliveira DB Eur J Immunol; 1995 Oct; 25(10):2899-906. PubMed ID: 7589090 [TBL] [Abstract][Full Text] [Related]
5. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Huugen D; Tervaert JW; Heeringa P Clin J Am Soc Nephrol; 2006 Sep; 1(5):1100-7. PubMed ID: 17699331 [TBL] [Abstract][Full Text] [Related]
6. Current state of biologicals in the management of systemic vasculitis. Lamprecht P; Till A; Steinmann J; Aries PM; Gross WL Ann N Y Acad Sci; 2007 Sep; 1110():261-70. PubMed ID: 17911441 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. Jennette JC; Xiao H; Falk RJ J Am Soc Nephrol; 2006 May; 17(5):1235-42. PubMed ID: 16624929 [TBL] [Abstract][Full Text] [Related]
8. Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: first report on the efficacy of primary anti-TNF-alpha treatment. Zaenker M; Arbach O; Helmchen U; Glorius P; Ludewig S; Braasch E Int J Tissue React; 2004; 26(3-4):85-92. PubMed ID: 15648440 [TBL] [Abstract][Full Text] [Related]
9. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Booth AD; Jayne DR; Kharbanda RK; McEniery CM; Mackenzie IS; Brown J; Wilkinson IB Circulation; 2004 Apr; 109(14):1718-23. PubMed ID: 15037536 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Deveci F; Muz MH; Ilhan N; Kirkil G; Turgut T; Akpolat N Respirology; 2008 Jun; 13(4):488-97. PubMed ID: 18410261 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. Schreiber A; Xiao H; Falk RJ; Jennette JC J Am Soc Nephrol; 2006 Dec; 17(12):3355-64. PubMed ID: 17108314 [TBL] [Abstract][Full Text] [Related]
19. B cell targeted therapies in autoimmune diseases. Isenberg DA J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442 [TBL] [Abstract][Full Text] [Related]
20. Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. Chen M; Wang F; Zhao MH Rheumatology (Oxford); 2009 Apr; 48(4):355-8. PubMed ID: 19181656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]